HCW Biologics Inc. announced the immediate exercise of certain outstanding warrants with an investor.
The warrant agreement includes the exercise of outstanding warrants issued in November 2024 and May 2025 at a reduced price of $2.66.
The gross proceeds from the warrant exercise are expected to be approximately $4.0 million.
Warrant Inducement Agreement
HCW Biologics entered into an agreement with an investor to exercise outstanding warrants at a reduced price.
Gross Proceeds
The exercise of warrants is expected to generate approximately $4.0 million before deducting fees and expenses.
Financial Advisor
Maxim Group LLC is representing HCW Biologics as the exclusive Financial Advisor for the transaction.
- The agreement is aimed at immediate exercising of existing warrants to raise capital for HCW Biologics.
- It demonstrates investor confidence in the company's future prospects.
This warrant inducement agreement signifies a significant financial move for HCW Biologics, allowing the company to raise funds and strengthen its financial position.